Tesamorelin

Tesamorelin

Tesamorelin (Egrifta/Egrifta SV) is the only FDA-approved GHRH analogue, indicated for the reduction of excess visceral fat in the stomach area in HIV-infected adults with lipodystrophy, with growing off-label interest from endocrinologists, anti-aging clinicians, and sports medicine physicians evaluating GH optimisation and body composition protocols. Licensed practitioners looking to buy Tesamorelin can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. Browse this page to learn more about Tesamorelin and its research applications through the overview and FAQ section below.

Is Tesamorelin FDA Approved? Identity, Benefits & Before and After

Tesamorelin peptide (TH9507; Egrifta/Egrifta SV) is a synthetic GHRH analogue developed by Theratechnologies. It has been the only FDA-approved GHRH analogue since its initial approval in November 2010, indicated for the reduction of excess visceral adipose tissue in HIV-infected adults with lipodystrophy.[3],[5] A higher-concentration formulation (Egrifta WR) received a Complete Response Letter from the FDA in January 2024 due to manufacturing and impurity concerns, but subsequently achieved FDA approval in March 2025 after those issues were resolved. Any use outside the approved HIV lipodystrophy indication is off-label and requires prescriber oversight, as of June 2026.

The most established Tesamorelin benefits are supported by Phase 3 RCTs in HIV-associated lipodystrophy.

• Falutz et al. (NEJM, 2007) reported approximately 18% visceral adipose tissue reduction versus placebo at 26 weeks.[1] A pooled analysis with safety extension data confirmed maintenance of this reduction at 52 weeks (Falutz et al., JCEM, 2010).[2]
• A 2024 study by Russo et al. confirmed that a 15 to 18% VAT reduction effect size remains valid in the modern integrase inhibitor-based ART era, with a 25 cm² VAT reduction at 12 months (p=0.001).[4]
• Human trial evidence consistently demonstrates reductions in visceral adipose tissue, increased endogenous GH secretion, elevated IGF-1, and improvements in body composition.[3]

Practitioners should distinguish visceral fat reduction from generalized weight loss: Tesamorelin primarily reduces fat in the stomach area, while overall body weight changes may be modest. GH and IGF-1 elevation has contributed to off-label interest in body composition and muscle growth applications, but these outcomes should be framed as extrapolated from approved-indication data, not as established FDA-approved efficacy findings.

Tesamorelin Before and After Expectations

Falutz et al. (NEJM, 2007) reported approximately 18% visceral adipose tissue reduction versus placebo at 26 weeks in HIV-associated lipodystrophy.[1] Extension studies demonstrated maintenance of this reduction through 52 weeks with continued therapy (Falutz et al., JCEM, 2010).[2]

For off-label body composition applications, outcomes are extrapolated from approved-indication studies and practitioner-reported experience, and should not be considered equivalent to FDA-approved efficacy findings.

How Tesamorelin Works: GHRH Mechanism & Growth Hormone Stimulation

Tesamorelin binds GHRH receptors on anterior pituitary somatotroph cells, stimulating pulsatile GH release and downstream IGF-1 production. This enhances endogenous GH secretion while maintaining physiologic regulatory pathways rather than replacing them with exogenous administration. At the tissue level, human clinical studies indicate that Tesamorelin preferentially reduces visceral adipose tissue while producing relatively limited changes in subcutaneous fat. This selective effect on fat in the stomach area is clinically relevant because visceral fat accumulation is associated with elevated cardiometabolic risk.

Tesamorelin has a reported plasma half-life of approximately 26 to 38 minutes (subcutaneous) but substantially shorter than DAC-modified CJC-1295. Daily administration is required. Available evidence indicates that physiologic GH pulsatility and somatostatin-mediated feedback remain intact during approved use, with no receptor downregulation observed at approved doses in Phase 3 trials.[5] Robust human safety data beyond 52 weeks remain limited, and this gap should be acknowledged in any protocol evaluation context.[2],[5]

Within the muscle growth and performance peptide category, GH and IGF-1 elevation mediates anabolic and metabolic downstream effects beyond visceral fat reduction, which forms the basis of off-label body composition interest. Robust clinical outcome data supporting performance enhancement in healthy individuals remain limited; most such applications are extrapolated or practitioner-reported.

Tesamorelin Dosage, Injection & Storage

The FDA-approved Tesamorelin dosage is 2 mg (Egrifta), 1.4 mg (Egrifta SV), or 1.28 mg (Egrifta WR) administered once daily via subcutaneous injection. Recommended injection sites include the abdomen, thigh, or upper arm, with routine rotation of sites to reduce local reactions. Appropriate needles and syringes per manufacturer instructions should be used. Tesamorelin is supplied as a lyophilized powder requiring reconstitution with the provided diluent. Following preparation, refrigeration at 2 to 8°C is required, with protection from light and use within the timeframe specified in current prescribing information.

For off-label body composition and GH optimisation protocols, dosing approaches are practitioner-reported and research-extrapolated. Practitioners commonly use 1 to 2 mg daily subcutaneously, but no validated off-label protocol exists. Individualized assessment and care team oversight are required, particularly for IGF-1 and glucose monitoring in research contexts where metabolic risk factors may be present.

Is Tesamorelin Safe? Side Effects & Legal Status

Tesamorelin has one of the most extensively characterized safety profiles among GHRH analogues, supported by Phase 3 RCT data from the LONO and LPTN trials in HIV-associated lipodystrophy. It is generally well tolerated at approved doses. Tesamorelin side effects include fluid retention, arthralgias, peripheral edema, carpal tunnel syndrome, and injection-site reactions including erythema and pruritus, as documented in Phase 3 trial safety data and the approved prescribing information.[3],[5] These effects are GH-mediated, dose-dependent, and typically manageable with appropriate monitoring.

Because Tesamorelin increases IGF-1, monitoring of IGF-1 concentrations and glucose metabolism is advisable, particularly for off-label use in research subjects with metabolic risk factors. Long-term safety data are more robust for the HIV-associated lipodystrophy indication than for other research contexts.

Current Regulatory Status

Tesamorelin has been FDA-approved as Egrifta/Egrifta SV for HIV lipodystrophy since November 2010, available by prescription only in the United States.[3],[5] The Egrifta WR formulation received FDA approval in March 2025 following resolution of manufacturing and impurity concerns that had resulted in a Complete Response Letter in January 2024. Compounded Tesamorelin products are not FDA-approved and should not be considered equivalent to branded formulations, as of June 2026.

Under the 2026 WADA Prohibited List, growth hormone secretagogues are prohibited in-competition under Class S2 (Peptide Hormones, Growth Factors, and Related Substances), as of June 2026. Competitive athletes should verify current status with their governing body before any use.

Tesamorelin vs Sermorelin & Tesamorelin vs CJC-1295

Tesamorelin and Sermorelin are both GHRH analogues that preserve somatostatin-mediated feedback and physiologic GH pulsatility, but their regulatory standing and evidence depth differ substantially. Tesamorelin is FDA-approved with Phase 3 visceral fat RCT data from the LONO and LPTN studies and a half-life of approximately 26 minutes. Sermorelin carries no current approval, no active Phase 3 evidence base, and a shorter half-life of approximately 10 to 20 minutes, though it has an established historical clinical profile and a previous FDA approval for pediatric GH deficiency withdrawn for commercial rather than safety reasons.[5] Tesamorelin is the stronger option where visceral fat-specific evidence and regulatory certainty are the deciding factors. Sermorelin may be preferred for physiologic GH optimisation in non-HIV contexts where nightly dosing alignment with nocturnal pulsatility is the priority. Researchers who choose to buy Sermorelin for those protocols can access sourcing guidance and documentation through Medical Spa Rx’s professional support team.

Tesamorelin and CJC-1295 both target the GHRH pathway but differ in pharmacokinetics, evidence quality, and regulatory standing. Tesamorelin requires once-daily subcutaneous injection, carries Phase 3 RCT data, and holds FDA approval — a materially different regulatory position than CJC-1295, which has a half-life of approximately 8 days enabling once-weekly dosing but operates entirely as a research compound without an approved indication.[5] Where regulatory confidence and human efficacy data are the priority, Tesamorelin is the more defensible choice. Where reduced injection frequency and research-context flexibility matter more, CJC-1295 may be considered, with the understanding that care team oversight operates without any approved prescribing framework to reference. Researchers evaluating extended-release GHRH analogues can review sourcing and documentation for those who choose to buy CJC-1295 through Medical Spa Rx’s professional support team.

Where Can Practitioners Buy Tesamorelin Online?

Practitioners looking to buy Tesamorelin online should source exclusively from suppliers who provide verifiable purity documentation, LOT number traceability, and a certificate of analysis. Given Tesamorelin’s prescription-only FDA status and the fact that compounded versions are not FDA-approved, confirming the regulatory and documentation standing of any supplier is especially important.

Tesamorelin should be sourced by qualified professionals only, operating within their local regulatory framework and maintaining clear on-label versus off-label distinctions. Those reviewing wholesale options should confirm COA availability and current regulatory compliance before placing an order. When buying Tesamorelin online, practitioners should also check for wholesale buying options that include batch-level documentation appropriate for research-grade procurement standards. Medical Spa Rx’s professional support team offers sourcing guidance and documentation support for licensed professionals evaluating qualified suppliers. Contact Medical Spa Rx’s professional support team directly for directions on verified sourcing.

FAQs

1. What is Tesamorelin — and is it FDA approved?

Tesamorelin (TH9507) is a synthetic GHRH analogue marketed as Egrifta and Egrifta SV, developed by Theratechnologies. It is the only currently FDA-approved GHRH analogue, indicated for the reduction of excess visceral adipose tissue in HIV-infected adults with lipodystrophy, as of June 2026. Off-label use is at prescriber discretion. Synonym: TH9507.

2. How does Tesamorelin work?

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile GH release and downstream IGF-1 production. It preferentially reduces visceral adipose tissue while preserving physiologic GH pulsatility and somatostatin-mediated feedback at approved doses. It does not administer exogenous GH.

3. What are the Tesamorelin benefits and before and after expectations?

Phase 3 RCT data demonstrate approximately 18% visceral adipose tissue reduction versus placebo at 26 weeks (Falutz et al., NEJM, 2007)[1] with maintenance through 52 weeks on continued therapy (Falutz et al., JCEM, 2010).[2] A 2024 study confirmed this effect size remains valid in the modern ART era.[4] Off-label body composition and GH optimisation outcomes are extrapolated from approved-indication studies and should not be equated with FDA-approved efficacy findings.

4. What is the Tesamorelin dosage?

The FDA-approved dosage is 2 mg subcutaneously once daily. Off-label protocols are practitioner-reported, typically 1 to 2 mg daily, with no validated off-label standard. All off-label use requires individualized assessment, care team oversight, and IGF-1 and glucose monitoring.

5. Is Tesamorelin safe — what are the side effects?

Phase 3 safety data from the LONO and LPTN trials support a generally favorable tolerability profile. Common side effects include fluid retention, arthralgias, peripheral edema, carpal tunnel syndrome, and injection-site reactions. IGF-1 and glucose monitoring is advisable given GH-mediated effects on insulin sensitivity.

6. How does Tesamorelin compare to Sermorelin and CJC-1295?

All three are GHRH analogues stimulating endogenous GH release. Tesamorelin is distinguished by FDA approval and Phase 3 visceral fat RCT evidence, with a half-life of approximately 26 minutes and daily dosing. Sermorelin has a historical clinical profile but no current approval. CJC-1295 with DAC has an approximately 8-day half-life enabling once-weekly dosing but operates as a research compound without an approved indication.

7. Where to buy Tesamorelin?

Licensed professionals evaluating Tesamorelin for research or prescribing contexts should prioritize verified purity documentation, COA availability, and regulatory compliance confirmation. Medical Spa Rx’s professional support team can provide sourcing guidance and documentation support for those assessing qualified suppliers.

Sources

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:1056/NEJMoa072375
2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490
3. Chong W. Egrifta (tesamorelin for injection) for subcutaneous use: full prescribing information. U.S. Food and Drug Administration. Published 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf
4. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. doi:10.1097/QAD.0000000000003965
5. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. doi:10.2165/11202240-000000000-00000

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.